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Acetylcholine, the principal vagus neurotransmitter, inhibits inflammation by suppressing the production of pro-
inflammatory cytokines through a mechanism dependent on the a7 nicotinic acetylcholine receptor subunit
(alpha7nAChR) that explains why vagus nerve stimulation is anti-inflammatory in nature. Strong expression of
alpha7nAChR in the synovium of rheumatoid arthritis and psoriatic arthritis patients was detected. Peripheral
macrophages and synovial fibroblasts respond in vitro to specific alpha7nAChR cholinergic stimulation with potent
inhibition of proinflammatory cytokines. Fibroblasts balance inflammatory mechanisms and arthritis development
through feedback cholinergic stimulation by nearby immune cells. Collagen induced arthritis in alpha7nAChR
(-/-)
mice was significantly severe and showed increased synovial inflammation and joint destruction compared to the
wild-type mice. Similar to vagal nerve stimulation and alpha7nAChR agonists, polyunsaturated fatty acids:
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) also suppress inflammation. In view of their similar
anti-inflammatory actions, it is proposed that vagal nerve stimulation, alpha7nAChR agonists and EPA and DHA
may augment the formation of anti-inflammatory lipid molecules: lipoxins, resolvins, protectins and maresins. This
implies that therapies directed at regulation of the cholinergic and alpha7nAChR mediated mechanisms and
enhancing the formation of lipoxins, resolvins, protectins and maresins may halt and/or ameliorate rheumatoid
arthritis, lupus and other rheumatological conditions.
Introduction
Rheumatoid arthritis (RA) is a chronic, inflammatory
autoimmune disease of unknown cause, characterized by
chronic synovial inflammation and progressive erosions
of cartilage and bone due to the release of excess cyto-
kines that stimulate the inflammatory reaction. Systemic
lupus erythematosus or lupus is also a chronic inflam-
matory autoimmune connective tissue disease that can
affect any part of the body resulting in inflammation
and tissue damage that often targets the heart, joints,
skin, lungs, blood vessels, liver, kidneys and nervous sys-
tem. Both RA and lupus show several overlapping fea-
tures though are considered clinically distinct entities.
Inflammation plays a major role in these and other
autoimmune diseases that involve a complex interaction
between several pro-inflammatory cytokines as well as
chemokines, neurotransmitters and other signalling
molecules.
Inflammation is at the core of the autoimmune dis-
eases that seem to arise through aberrant reactions of
the human adaptive or innate immune systems due to
the activation of the patient’s immune system against
the body’so w np r o t e i n s .A sar e s u l t ,as e r i e so fp r o -
inflammatory molecules such as tumor necrosis factor-a
(TNF-a), interleukin-6 (IL-6), macrophage migration
inhibitory factor (MIF), interferon (IFN), high-mobility
group box-1 (HMGB-1), free radicals, myeloperoxidase
and inducible nitric oxide (iNO) are released that initi-
ate and perpetuate the inflammatory process. Though
the exact cause for autoimmune disorders is not known,
it is clear that methods designed to suppress the aber-
rant inflammatory response are of significant help in
giving relief to the patients. For this purpose, non-steroi-
dal anti-inflammatory compounds, corticosteroids, anti-
TNF-a, and immunosuppressive drugs are widely used
in the management of rheumatoid arthritis (RA) and
lupus and other autoimmune diseases [1]. Despite the
use of these drugs, majority of the patients continue to
suffer from the various manifestations of these diseases
and relatively few attain complete remission.
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various drugs used in their treatment that are not with-
out significant side-effects. In view of this, it is impera-
tive that newer approaches are needed to manage RA,
lupus and other related conditions.
Recent studies suggested that cholinergic mechanisms
regulate immune function. T and B cells and macro-
phages have the ability to produce acetylcholine (ACh)
and enzymes involved in ACh production, i.e. choline
acetyl transferase (ChAT) [2-4]. These cell types also
express various cholinergic receptors on their surface.
Of all, nicotinic receptors with the subtype a7 (alpha7-
nAChR) have significant effects on immune regulation
[4]. Specific stimulation of alpha7nAChR on monocytes
suppresses pro-inflammatory cytokine production
termed as the cholinergic antiinflammatory pathway
[5-8]. These evidences suggest that cholinergic antiin-
flammatory pathway could be exploited to suppress
inflammation seen in RA, lupus and other autoimmune
diseases.
Synovial tissue express alpha7nAChR
Recent studies revealed that alpha7nAChR is present in
the synovial tissue of healthy volunteers. In the synovial
sublining, alpha7nAChR was found to be expressed in
scattered cells with macrophage- and fibroblast-like
morphology. Strong staining of alpha7nAChR was
detected in perivascular endothelial-like cells with visible
vessels. Alpha7nAChR is detected in synovial tissue of
all RA and psoriatic arthritis patients and is especially
present in the synovial lining layer than the sublining.
In patients with follicular mononuclear infiltrates, the
alpha7nAChR expression was mainly observed in cells
with macrophage like morphology. Furthermore, macro-
phages (expressing CD68 and CD163) were found to
strongly express alpha7nAChR as well as fibroblasts, in
occasional T cells (CD3) and B cells (CD19) including
plasma cells (CD138) and CD19 positive cells in a
mononuclear infiltrate [9]. These results suggest that
specific expression of cholinergic receptors is seen in
the synovium of normal and those with RA and psoria-
sis. In addition, several cell types in the arthritis syno-
vium are capable of cholinergic stimulation. Based on
these studies, it was opined that the diversity in choli-
nergic immune regulation mayc o n t r i b u t et ot h ed i f f e r -
ent pathological and clinical features of RA and
psoriatic arthritis. The presence of alpha7nAChR in
macrophages, T cells, B cells and plasma cells suggest
that specific cholinergic mechanisms may be involved in
regulation of antibody production locally in the joint.
Cholinergic mechanisms may also influence synovial
production of autoantibodies that are known to be
involved in RA pathogenesis. The presence of alpha7-
nAChR receptors on endothelial cells might contribute
to the regulation of endothelial cell proliferation and
migration [10,11] and angiogenesis [12] and thus,
cholinergic mechanisms may have an impact in the
pathobiology of arthritis.
Cholinergic anti-inflammatory pathway
Central nervous system is known to have a regulatory
role in the production of pro-inflammatory cytokines:
tumor necrosis factor-a (TNF-a), interleukin-1 (IL-1),
high mobility group box 1 (HMGB1), IL-6, and macro-
phage migration inhibitory factor (MIF) through the
efferent vagus nerve [13-15]. Acetylcholine, the princi-
pal vagus neurotransmitter, inhibits the production of
pro-inflammatory cytokines through a mechanism
dependent on the a7 nicotinic acetylcholine receptor
subunit (alpha7nAChR). Thus, vagus nerve stimulation
controls the production of pro-inflammatory cytokines.
Since strong expression of alpha7nAChR is seen in the
synovium of normal, RA and psoriatic arthritis patients
[9], and both peripheral macrophages and synovial
fibroblasts respond to specific alpha7nAChR choliner-
gic stimulation with potent inhibition of proinflamma-
tory cytokines [13-15], it is likely that fibroblasts,
especially in the lining layer, balance inflammatory
mechanisms and arthritis development through feed-
back cholinergic stimulation by nearby immune cells.
These evidences suggest that new therapies directed at
regulation of the cholinergic and alpha7nAChR
mediated mechanisms could be of benefit in the man-
agement of lupus, RA and other related inflammatory
and immune disorders.
Cholinergic anti-inflammatory pathway is
depressed in RA
This proposal is supported by the observation that RR
interval variability (heart rate variability, HRV) that is a
marker of vagus nerve tone (that reflects parasympa-
thetic activity), in RA patients was significantly
depressed compared to control [16]. These findings
imply that it is possible to pharmacologically target the
alpha7nAChR dependent control of cytokine release in
RA patients who have suppressed vagus nerve activity.
Alpha7nAChR agonists ameliorated the clinical course
of collagen induced arthritis in animals [17]: arthritis
was exacerbated by vagotomy and suppressed by oral
nicotine administration; oral nicotine inhibited bone
degradation and reduced TNF-a expression in synovial
tissue, and ameliorated clinical arthritis and reduced
synovial inflammation that was accompanied by a reduc-
tion of TNF-a level in both plasma and synovial tissue.
Histopathological studies showed that nicotine reduced
infiltration of inflammatory cell and bone destruction,
and decreased expression of TNF-a and IL-6 but did
not alter IL-10 levels. Nicotine also reduced the
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joints of collagen-induced arthritis mice [18].
Furthermore, RR interval variability in RA patients was
significantly decreased as compared with controls.
HMGB1 levels and RR interval variability were signifi-
cantly related. HMGB1 serum levels significantly corre-
lated with disease activity scores in patients with RA.
These results are consistent with the hypothesis that
decreased cholinergic anti-inflammatory pathway activity
is associated with increased HMGB1 levels in patients
with RA [19].
It was reported that RR interval variability, in RA
patients was significantly depressed compared to normal
control. In the same group of RA patients, whole blood
cultures stimulated by endotoxin produced significantly
less TNF as compared to healthy controls. Addition of
cholinergic agonists to the stimulated whole blood cul-
tures however significantly suppressed cytokine produc-
tion to a similar extent in patients and healthy controls
[16]. In addition, nicotine reduced the protein and
mRNA expression of IL-6 and IL-8 induced by TNF-a,
inhibited nuclear factor (NF)-kappaB (p65) translocation
from the cytoplasm to the nucleus [20,21]. These results
suggest that alpha7nAChR agonists modulate the release
of pro-inflammatory cytokines and thus, are of signifi-
cant benefit in RA.
Furthermore, collagen-induced arthritis in alpha7-
nAChR
(-/-) mice was significantly severe and showed
increased synovial inflammation and joint destruction
compared to the wild-type mice. Exacerbation of the
arthritis was associated with elevated systemic proin-
flammatory cytokines and enhanced T-helper cell 1
(Th1)-cytokine and TNF-a production by spleen cells
[22]. These results suggest that immune cell function in
a model of rheumatoid arthritis is regulated by the cho-
linergic system and, at least in part, mediated by the
alpha7nAChR206. These results imply that vagus nerve
stimulation could be employed in the treatment of
lupus, RA and other autoimmune and inflammatory
diseases.
Interaction(s) between acetylcholine and
polyunsaturated fatty acids
Exogenously added and endogenously produced arachi-
donic acid (AA) increased the evoked release of acetyl-
choline from rat hippocampal nerve terminals [23] and
possibly, other tissues. Muscarinic activation triggers AA
production. AA may act as a facilitatory retrograde mes-
senger in hippocampal cholinergic muscarinic transmis-
sion in view of the ability of AA to enhance
acetylcholine release. In a similar fashion, dietary doco-
sahexaenoic acid (DHA) enhanced potassium chloride-
evoked release of acetylcholine in rat hippocampus [24],
suggesting that acetylcholine release is regulated by
polyunsaturated fatty acids (PUFAs) [1,25-28]. Acetyl-
choline and PUFA-derived lipoxins, resolvins, protectins
and maresins have anti-inflammatory actions. But it is
not known whether acetylcholine can actually enhance
the formation anti-inflammatory lipoxins, resolvins, pro-
tectins and maresins. In all probability it does.
Acetylcholine and PUFA metabolism
Torpedo electric organ readily synthesizes prostaglandin
E2 (PGE2) from both exogenous and endogenous arachi-
donate and activation of the presynaptic muscarinic
acetylcholine receptor increases the rate of PGE2 synth-
esis by inducing the release of tissue AA from its phos-
pholipid pools. Torpedo electric organ slices also
synthesize PGE2 from endogenous substrates. Activation
of the Torpedo muscarinic acetylcholine receptor
resulted in a dose-dependent increase in the synthesis of
PGE2 from endogenous AA. These results suggest that
activation of the muscarinic acetylcholine receptor
enhances the formation of PGE2 [29].
Acetylcholine significantly increased the efflux of PGE
and PGF from brain regions enriched in muscarinic
cholinergic receptors, i.e., cerebral cortex, temporal cor-
tex, corpus striatum, and hippocampus that was inhib-
ited by atropine, while norepinephrine, histamine, and
serotonin were ineffective in stimulating PG release
from brain cortex slices [30]. Acetylcholine augments
the formation of prostacyclin (PGI2), a potent vasodila-
tor and anti-inflammatory molecule [31,32]. These evi-
dences suggest that acetylcholine modulates PUFA
metabolism and enhances the formation of PGE2 and
PGI2. Hence, it is likely that acetylcholine may augment
the formation of lipoxins, resolvins, protectins and mar-
esins. This is especially so since, acetylcholine and lipox-
ins, resolvins and protectins have anti-inflammatory
actions. Thus, acetylcholine and PUFAs may serve as
endogenous anti-inflammatory molecules. Similar to the
ability of acetylcholine and VNS that ameliorate insulin
resistance, even PUFAs reduce insulin resistance
[33-35]. This implies that one potential mechanism by
which acetylcholine produces its anti-inflammatory
action is by enhancing the formation of lipoxins, resol-
vins, protectins and maresins from PUFAs. Thus, it
appears that PUFAs augment release of acetylcholine,
while acetylcholine enhances the conversion of PUFAs
to anti-inflammatory lipoxins, resolvins, protectins and
maresins. Such an interaction between acetylcholine and
PUFAs may explain their anti-inflammatory nature and
possible beneficial action of VNS in inflammatory condi-
tions such as RA and lupus [17-22,36-40].
Hypothesis
It is evident from the preceding discussion that vagus
nerve stimulation suppresses inflammation, alpha7nAChR
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tis, especially in animal models of arthritis whereas arthri-
tis could be exacerbated by vagotomy and suppressed by
oral nicotine administration; oral nicotine and/or alpha7-
nAChR agonists inhibit bone degradation and reduced
TNF-a expression in synovial tissue and reduced synovial
inflammation (see Figure 1). Thus, vagal tone plays an
important role in the pathobiology of inflammation and
RA and possibly, other related conditions. Hence, it is pro-
posed that in subjects with RA, lupus and other
autoimmune inflammatory diseases the vagal tone is sub-
normal and sympathetic tone is high. Acetylcholine, the
principal vagal neurotransmitter, suppresses inflammation
by inhibiting proinflammatory cytokine release through a
mechanism that requires alpha7nAChR [6,36-42], while
catecholamines have proinflammatory actions [43,44].
Insulin resistance seen in RA, lupus and other autoim-
mune diseases could also be attributed to reduced vagal
tone since, vagus has a regulatory role in insulin secretion
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protectins and maresins 
Steroids, anti-TNF-α drugs, IL-6 receptor antagonists, 
azathioprine, cyclophosphamide, cyclosporine, Leflunomide, etc. 
Figure 1 Scheme showing the interaction among VNS, cytokines and PUFAs and their anti-inflammatory metabolites lipoxins,
resolvins, protectins and maresins and their role in RA, lupus and IBD.
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Furthermore, acetylcholine and VNS ameliorate insulin
resistance, in part, by enhancing the release of cholecysto-
kinin and incretins [48].
As discussed above, VNS and PUFAs seem to interact
with each other such that they potentiate each other’s
actions. Both VNS and PUFAs (and their products
lipoxins, resolvins, protectins, maresins and PGI2)h a v e
anti-inflammatory actions, reduce insulin resistance, and
are useful in the prevention and management of cardio-
vascular diseases and cardiac arrhythmias
[7,8,11,26-28,34,36,45-50]. Iti sl i k e l yt h a ti np a t i e n t s
with RA, lupus and other autoimmune diseases and
inflammatory conditions such as inflammatory bowel
diseases, vagal tone will be subnormal and sympathetic
tone is high; synovial fibroblasts, infiltrating (into the
involved joints) macrophages, T cells and leukocytes
may show reduced number or defective expression of
alpha7nAChR and their content of PUFAs (especially
AA, EPA and DHA) and ability to form adequate
amounts of lipoxins, resolvins, protectins and maresins
will be defective; and even the plasma and synovial fluid
content of PUFAs and concentrations of lipoxins, resol-
vins, protectins and maresin sa r el i k e l yt ob el o w .I ti s
also proposed that there could be a defect in the synth-
esis (or inadequate formation) of lipoxins, resolvins, pro-
tectins and maresins from PUFAs and in response to
alpha7nAChR and VNS in those who respond poorly to
treatment and who have aggressive RA and lupus auto-
immune diseases and inflammatory conditions such as
inflammatory bowel diseases.
Testing the hypothesis
It is proposed that reduced vagal tone triggers increased
production of IL-6, TNF-a,M I Fa n dH M G B 1b yp e r -
ipheral leukocytes, monocytes and macrophages; leads
to an increase in sympathetic activity (due to the
absence of negative feed-back control from the parasym-
pathetic system), and consequent inflammation due to a
decrease in the production of anti-inflammatory acetyl-
choline that ultimately results in systemic inflammation
seen in RA and lupus. Hence, it is expected that an
increase in plasma catecholamines and decrease in acet-
ylcholine (and also in the synovial cells, peripheral leu-
kocytes, macrophages and T cells) occurs in these
patients. Peripheral leukocytes, macrophages and T cells
and synovial cells obtained from the involved joint can
be used for measuring the concentrations of catechola-
mines and acetylcholine in these subjects since they
contain the complete intracellular machinery for the
generation, release and inactivation of these molecules.
Thus, measurement of catecholamines and acetylcholine
in the plasma and peripheral leukocytes and vagal tone
by HRV could be used as markers of inflammation and
to predict, prognosticate and gauge response to treat-
ment in patients with RA and lupus. In addition, plasma
and tissue (especially of peripheral leukocytes, macro-
phages and T cells and synovial cells) concentrations of
AA, EPA and DHA and their products lipoxins, resol-
vins, protectins and maresins are likely to be low in
patients with RA and lupus. A negative correlation
could exist between plasma, synovial, and leukocyte,
macrophage and T cell content of acetylcholine, AA,
EPA, DHA, lipoxins, resolvins, protectins and maresins
and the severity of RA and lupus. It is proposed that
VNS enhances the formation of lipoxins, resolvins, pro-
tectins and maresins from their precursor PUFAs. This
could be verified by studying the effect of alpha7nAChR
agonists on the synthesis and release of lipoxins, resol-
vins, protectins and maresins from PUFAs by leuko-
cytes, macrophages, T cells, synovial cells and other
cells in vitro. Similarly, in experimental animals and
humans the ability of VNS to augment the formation of
lipoxins, resolvins, maresins and protectins in various
tissues and enhance their levels in the plasma could be
assessed.
Conclusions
The proposal that vagal tone is decreased, sympathetic
tone is enhanced and increased production of IL-6,
TNF-a, MIF and HMGB1 and decrease in plasma and
tissue concentrations of AA, EPA and DHA and their
products lipoxins, resolvins, protectins and maresins
occurs in RA and lupus has important therapeutic
implications. If true, it implies that methods designed
to block a2 -adrenoreceptors [(since blocking these
receptor inhibits inflammation injury due to catechola-
mines [43]], stimulation of the vagus nerve [8] and the
nicotinic acetylcholine receptor a7 subunit [6] and
supplementation of AA, EPA and DHA and adminis-
tration of lipoxins, resolvins, protectins and maresins
or their stable synthetic analogues are expected to be
of significant benefit in the prevention and manage-
ment of RA, lupus and inflammatory bowel diseases
(Figure 1).
In an animal model wherein colitis was induced by
intracolonic instillation of dinitrobenzene sulfonic acid,
VNS (left cervical) reduced the degree of body weight
loss, inflammatory markers as observed by histological
score and myeloperoxidase quantification and an
improvement of the multivariate index of colitis was
noted. These data lend further support for an anti-
inflammatory role of VNS in rats with colitis and pro-
vide potential therapeutic applications for patients with
inflammatory bowel disease [51].
Similar to the beneficial action of VNS in inflamma-
tory bowel disease, lipoxins (derived from PUFAs) are
also useful in resolving inflammatory bowel disease. LXs
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patients with ulcerative colitis produced significantly
lower (12-fold) amounts of LXA4 compared with control
[52], and mice chronically treated with a selective 15-
lipoxygenase inhibitor experienced significantly worse
intestinal function during experimental colitis, relative
to untreated mice. On the other hand, an orally effective
and a beta-oxidation-resistant 3-oxa- aspirin-triggered
15-epi-lipoxin (ATL) analog (ZK-192) markedly attenu-
ated trinitrobenzenesulphonate (TNBS)-induced colitis.
ZK-192 decreased mucosal mRNA levels of inflamma-
tory mediators: inducible nitric oxide synthase, cyclooxy-
genase 2, and macrophage inflammatory protein 2, also
decreased mucosal mRNA and protein levels of T helper
1 effector cytokines: TNF-a,I L - 2 ,a n dI F N - g and
reduced the systemic levels of these cytokines. ZK-192
also dramatically attenuated CD3/CD28-mediated costi-
mulation of T helper 1 effector cytokine release in
lamina propria mononuclear cells [53]. Thus, both VNS
and LXs have similar anti-inflammatory actions in RA,
lupus and inflammatory bowel disease.
Vagal nerve stimulation (VNS) is already in clinical
use as an adjunctive treatment for certain types of
intractable epilepsy and major depression [54,55]. VNS
uses an implanted stimulator that sends electric
impulses to the left vagus nerve in the neck via a lead
wire implanted under the skin. The advantage of VNS is
that it can be done as an out-patient procedure. It is
possible to pharmacologically target the alpha7nAChR
dependent control of cytokine release in RA and lupus
patients with suppressed vagus nerve activity. As alpha7-
nAChR agonists ameliorate the clinical course of col-
lagen induced arthritis in animals, it may be possible in
the future to explore whether alpha7nAChR agonists
can improve clinical activity in RA and lupus patients.
In this context, it will be interesting to study the effect
of steroids, anti-TNF-a drugs, immunosuppressive drugs
such as azathioprine, cyclophosphamide, cyclosporine,
etc., on their ability to modulate alpha7nAChR and
vagal tone and the formation of lipoxins, resolvins, pro-
tectins and maresins from various PUFAs and are thus,
able to bring about some of their beneficial actions in
RA and lupus. It is likely that in future in addition to
the currently available treatment regimens one could
employ VNS and alpha7nAChR agonists, stable and syn-
thetic analogues of lipoxins, resolvins, protectins and
maresins in the management of RA, lupus, inflammatory
bowel diseases and other inflammatory and autoimmune
disorders.
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